Furthermore, preclinical and clinical studies are currently investigating the potential use of the H3 receptor antagonists for the treatment of cognitive disorders such as Alzheimer's disease (6,7).
Effects of histamine H3 receptor antagonists in two models of spatial learning.
Ziarco's pipeline includes a histamine H4 receptor antagonist programme, with a lead compound that has completed a Phase 1 multiple ascending dose study; a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor; histamine H3 receptor antagonists possessing CNS-sparing properties, with a lead compound in advanced preclinical development; as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.
The pipeline is completed by a histamine H3 receptor antagonist programme possessing CNS-sparing properties which is in advanced preclinical development and an early-stage spleen tyrosine kinase (SYK) inhibitor programme suitable for topical administration.
Nasdaq: GLIA) today announced that researchers at Stanford University School of Medicine have identified wake promoting or vigilant-promoting properties in Gliatech's novel histamine H3 receptor antagonists.
The current study contrasted the wake-promoting profile of the Gliatech compounds with classical psychomotor stimulants and found that for the histamine H3 receptor antagonists, these compounds did not result in the side effects associated with classical stimulants.
Consequently, these H3 receptor antagonists may prove to be useful in promoting attention and wakefulness.
The Phase I SBIR grant will be utilized to evaluate Gliatech's lead H3 receptor antagonists
in preclinical models of ADD.